Reduction of intracellular pH as a strategy to enhance the pH-dependent cytotoxic effects of melphalan for human breast cancer cells

Clinical Cancer Research

Volumn 11, Issue 9, 2005, Pages 3553-3557

  Wong, Philip ^a   Lee, Carol ^a   Tannock, Ian F ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BICARBONATE CHLORIDE ANTIPORTER; BICARBONATE CHLORIDE ANTIPORTER BLOCKING AGENT; BLOCKING AGENT; CARIPORIDE; MELPHALAN; S 3705; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER CELL DESTRUCTION; CELL PH; CELL PROLIFERATION; CELL STRAIN MCF 7; CULTURE MEDIUM; DRUG CYTOTOXICITY; DRUG EFFICACY; HUMAN; HUMAN CELL; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS, ALKYLATING; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; CHLORIDE-BICARBONATE ANTIPORTERS; CULTURE MEDIA; GUANIDINES; HUMANS; HYDROGEN-ION CONCENTRATION; INTRACELLULAR FLUID; MELPHALAN; SODIUM-HYDROGEN ANTIPORTER; SULFONES; TIME FACTORS;

EID: 18244394303     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-04-2472     Document Type: Article

References (28)

1. Born R, Eichholtz-Wirth H. Effect of different physiological conditions on the action of Adriamycin on Chinese hamster cells in vitro. Br J Cancer 1981;44:241-6.
2. Hindenburg AA, Gervasoni JE Jr, Krishna S, et al. Intracellular distribution and pharmacokinetics of daunorubicin in anthracycline-sensitive and -resistant HL-60 cells. Cancer Res 1989;49:4607-14.
3. Jahde E, Glusenkamp KH, Rajewsky MF. Protection of cultured malignant cells from mitoxantrone cytotoxicity by low extracellular pH: a possible mechanism for chemoresistance in vivo. Eur J Cancer 1990;26:101-6.
4. Vukovic V, Tannock IF. Influence of low pH on cytotoxicity of paclitaxel, mitoxantrone and toptecan. Br J Cancer 1997;75:1167-72.
5. Ferguson PJ, Phillips JR, Selner M, Cass CE. Differential activity of vincristine and vinblastine against cultured cells Cancer Res 1984;44:3307-12.
6. Brophy GT, Sladek NE. Influence of pH on the cytotoxic activity of chlorambucil. Biochem Pharmacol 1983;32:79-84.
7. Mikkelsen RB, Asher C, Hicks T. Extracellular pH, transmembrane distribution and cytotoxicity of chlorambucil. Biochem Pharmacol 1985;34:2531-4.
8. Miller L, Deffie AM, Bose R, Goldenberg GJ. Modulation of melphalan uptake in murine L5178Y lymphoblasts in vitro by changes in ionic environment. Biochem Pharmacol 1992;43:1154-8.
9. Skarsgard LD, Skwarchuk MW, Vinczan A, Kristl J, Chaplin DJ. The cytotoxicity of melphalan and its relationship to pH, hypoxia and drug uptake. Anticancer Res 1995;15:219-23.
10. Siemann DW, Chapman M, Beikirch A. Effects of oxygenation and pH on tumour cell response to alkylating chemotherapy. Int J Radiat Oncol Biol Phys 1991;20:287-9.
11. Wood PJ, Sansom JM, Newell K, Tannock IF, Stratford IJ. Reduction of tumour intracellular pH and enhancement of melphalan cytotoxicity by the ionophore Nigericin. Int J Cancer 1995;60:264-8.
12. Kuin A, Aalders M, Lamfers M, et al. Potentiation of anti-cancer drug activity at low intratumoural pH induced by the mitochondrial inhibitor m-iodobenzylguanidine (MIBG) and its analogue benzylguanidine (BG). Br J Cancer 1999;79:793-801.
13. Davis AJ, Tannock IF. Repopulation of tumour cells between cycles of chemotherapy: a neglected factor. Lancet Oncol 2000;1:86-93.
14. Wu L, Tannock IF. Repopulation in murine breast tumors during and after sequential treatments with cyclophosphamide and 5-fluorouracil. Cancer Res 2003;63:2134-8.
15. Withers HR, Taylor JM, Maciejewski B. The hazard of accelerated tumour clonogen repopulation during radiotherapy. Acta Oncol 1988;27:131-46.
16. Maciejewski B, Withers HR, Taylor JM, Hliniak A. Dose fractionation and regeneration in radiotherapy for cancer of the oral cavity and oropharynx: tumour dose-response and repopulation. Int J Radiat Oncol Biol Phys 1989;16:831-43.
17. Stephens TC, Peacock JH. Tumour volume response, initial cell kill and cellular repopulation in B16 melanoma treated with cyclophosphamide and 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea. Br J Cancer 1977;36:313-21.
18. Durand RE, Vanderbyl SL. Tumor resistance to therapy: a genetic or kinetic problem? Cancer Commun 1989;1:277-83.
19. Milas L, Nakayama T, Hunter N, et al. Dynamics of tumor cell clonogen repopulation in a murine sarcoma treated with cyclophosphamide. Radiother Oncol 1994;30:247-53.
20. Wong P, Kleemann HW, Tannock IF. Cytostatic potential of novel agents that inhibit the regulation of intracellular pH. Br J Cancer 2002;87:238-45.
21. Pruijn FB, van Daalen M, Holford NH, Wilson WR. Mechanisms of enhancement of the antitumour activity of melphalan by the tumour-blood-flow inhibitor 5,6-dimethylxanthenone-4-acetic acid. Cancer Chemother Pharmacol 1997;39:541-6.
22. Ross WE, Ewig RA, Kohn KW. Differences between melphalan and nitrogen mustard in the formation and removal of DNA cross-links. Cancer Res 1978;38:1502-6.
23. Parsons PG. Dependence on treatment time of melphalan resistance and DNA cross-linking in human melanoma cell lines. Cancer Res 1984;44:2773-8.
24. Osborne MR, Lawley PD, Crofton-Sleigh C, Warren W. Products from alkylation of DNA in cells by melphalan: human soft tissue sarcoma cell line RD and Escherichia coli WP2. Chem Biol Interact 1995;97:287-96.
25. Laurencot CM, Kennedy KA. Influence of pH on the cytotoxicity of cisplatin in EMT6 mouse mammary tumor cells. Oncol Res 1995;7:371-9.
26. Pu Q, Bianchi P, Bezwoda WR. Alkylator resistance in human B lymphoid cell lines: (1). Melphalan accumulation, cytotoxicity, interstrand-DNA- crosslinks, cell cycle analysis, and glutathione content in the melphalan-sensitive B-lymphocytic cell line (WIL2) and in the melphalan-resistant B-CLL cell line (WSU-CLL). Anticancer Res 2000;20:2561-8.
27. Montcourrier P, Silver I, Farnoud R, Bird I, Rochefurt M. Breast cancer cells have a high capacity to acidify extracellular milieu by a dual mechanism. Clin Exp Metastasis 1997;15:382-92.
28. + ATPase in daunorubicin distribution in etoposide-resistant MCF7 cells overexpresing the multidrug-resistance associated protein. Int J Oncol 1998;12:711-5.